More good Phase III Xanelim results

Xoma (XOMA) and partner Genentech (DNA) reported that 22% and 28% of patients treated for 12 weeks with 1 mg/kg and 2 mg/kg of Xanelim, respectively, reached the primary end point of > = 75% reduction...